Abstract: Slide Presentations |

“Stepping Down” from Fluticasone Propionate/Salmeerol 100/50mcg Diskus® Results in Loss of Asthma Control: Lack of Effect of Ethnic Origin FREE TO VIEW

Paul M. Dorinsky, MD*; John Stauffer, MD; Kelli Waitkus-Edwards, PhD; Steve Yancey, MS; Barbara A. Prillaman, MS; Laura Sutton, PharmD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest. 2004;126(4_MeetingAbstracts):758S. doi:10.1378/chest.126.4_MeetingAbstracts.758S-a
Text Size: A A A
Published online


PURPOSE:  To determine if asthma subjects of different ethnic origin adequately controlled on fluticasone propionate (FP)/salmeterol (SAL) 100/50mcg (FSC) differ in maintenance of control when therapy is stepped-down to FP, SAL, or montelukast (MON) compared with continuing FSC.

METHODS:  After 2 weeks on current ICS therapy, all subjects in two identical studies received FSC 100/50mcg BID for 4 weeks and were then randomized to continue FSC or step-down to FP 100mcg BID, SAL 50mcg BID or MON 10mg QD for 16 weeks.

RESULTS:  Change from Baseline at Endpoint (SE).

CONCLUSION:  Asthma control was maintained to a similar degree with FSC, regardless of ethnic origin. Once asthma control is achieved with FSC, stepping-down to FP, SAL or MON results in loss of asthma control in both Caucasians and African Americans.

CLINICAL IMPLICATIONS:  This study confirms that maintaining asthma control by treating both inflammation and smooth muscle dysfunction is superior to treating either component alone. (SAS40036/37). CaucasiansFSC 100/50 BID (n=284)FP 100 BID (n=276)SAL 50 BID (n=266)MON 10 QD (n=280)AM PEF (L/min)4.3 (2.6)*−15.3 (2.6)−22.3 (2.7)−31.2 (2.6)FEV1 (L)0.08 (0.03)*−0.05 (0.03)−0.14 (0.04)−0.24 (0.03)%Symptom-free Days4.1 (2.1)*−2.4 (2.1)−6.3 (2.2)−12.9 (2.1)%Rescue-free Days6.3 (2.4)*−9.9 (2.3)−13.3 (2.4)23.2 (2.3)Exacerbations, n (%)9 (3)19 (6)45 (14)43 (13)African AmericansFSC 100/50 BID (n=21)FP 100 BID (n=24)SAL 50 BID (n=25)MON 10 QD (n=24)AM PEF (L/min)−1.2 (15.4)−10.9 (14.6)−16.1 (12.8)−17.5 (12.8)FEV1 (L)0.00 (0.15)−0.18 (0.15)−0.23 (0.13)−0.30 (0.13)%Symptom-free Days9.1 (11.8)−15.5 (11.4)17.1 (10.1)−5.0 (10.4)%Rescue-free Days22.2 (11.4)−27.7 (11.1)10.3 (10.1)−1.0 (10.6)Exacerbations, n (%)1 (<1)1 (<1)4 (1)2 (<1)*

p≤0.020 for FSC vs. FP, SAL, and MON

DISCLOSURE:  P.M. Dorinsky, None.

Tuesday, October 26, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543